المؤلفون: Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP, US National Cancer Institute. Organ Dysfunction Working Group, Ramanathan, Ramesh K, Egorin, Merrill J, Takimoto, Chris H M, Remick, Scot C

المصدر: Journal of Clinical Oncology; 2/1/2008, Vol. 26 Issue 4, p563-569, 7p

المؤلفون: Sikic BI; 1 Stanford University School of Medicine, Stanford, CA., Lakhani N; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Patnaik A; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Shah SA; 1 Stanford University School of Medicine, Stanford, CA., Chandana SR; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Rasco D; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Colevas AD; 1 Stanford University School of Medicine, Stanford, CA., O'Rourke T; 2 South Texas Accelerated Therapeutics Midwest, Grand Rapids, MI., Narayanan S; 1 Stanford University School of Medicine, Stanford, CA., Papadopoulos K; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Fisher GA; 1 Stanford University School of Medicine, Stanford, CA., Villalobos V; 4 University of Colorado Cancer Center, Aurora, CO., Prohaska SS; 1 Stanford University School of Medicine, Stanford, CA., Howard M; 1 Stanford University School of Medicine, Stanford, CA., Beeram M; 3 South Texas Accelerated Therapeutics, San Antonio, TX., Chao MP; 5 Forty Seven, Menlo Park, CA., Agoram B; 5 Forty Seven, Menlo Park, CA., Chen JY; 5 Forty Seven, Menlo Park, CA., Huang J; 5 Forty Seven, Menlo Park, CA., Axt M; 5 Forty Seven, Menlo Park, CA., Liu J; 5 Forty Seven, Menlo Park, CA., Volkmer JP; 5 Forty Seven, Menlo Park, CA., Majeti R; 1 Stanford University School of Medicine, Stanford, CA.; 5 Forty Seven, Menlo Park, CA., Weissman IL; 1 Stanford University School of Medicine, Stanford, CA., Takimoto CH; 5 Forty Seven, Menlo Park, CA., Supan D; 1 Stanford University School of Medicine, Stanford, CA., Wakelee HA; 1 Stanford University School of Medicine, Stanford, CA., Aoki R; 1 Stanford University School of Medicine, Stanford, CA., Pegram MD; 1 Stanford University School of Medicine, Stanford, CA., Padda SK; 1 Stanford University School of Medicine, Stanford, CA.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2019 Apr 20; Vol. 37 (12), pp. 946-953. Date of Electronic Publication: 2019 Feb 27.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*administration & dosage , Lymphoma/*drug therapy , Neoplasms/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/immunology ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/immunology ; Antineoplastic Agents, Immunological/pharmacokinetics ; Biopsy ; CD47 Antigen/immunology ; Cohort Studies ; Female ; Humans ; Lymphoma/immunology ; Lymphoma/metabolism ; Lymphoma/pathology ; Male ; Middle Aged ; Neoplasms/immunology ; Neoplasms/metabolism ; Neoplasms/pathology

المؤلفون: Maki RG; Melanoma-Sarcoma Program, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA. makir@mskcc.org, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachère NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2009 Jul 01; Vol. 27 (19), pp. 3133-40. Date of Electronic Publication: 2009 May 18.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Benzenesulfonates/*therapeutic use , Neoplasm Recurrence, Local/*drug therapy , Pyridines/*therapeutic use , Sarcoma/*drug therapy, Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacokinetics ; Benzenesulfonates/pharmacokinetics ; Disease-Free Survival ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Niacinamide/analogs & derivatives ; Phenylurea Compounds ; Pyridines/pharmacokinetics ; Sarcoma/mortality ; Sorafenib ; Young Adult

المؤلفون: Tolcher AW; Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, USA. atolcher@start.stoh.com, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, Keating A, Antonia S

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2008 Nov 10; Vol. 26 (32), pp. 5198-203. Date of Electronic Publication: 2008 Sep 29.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Antineoplastic Agents/*pharmacokinetics , Apoptosis/*drug effects , Imidazoles/*administration & dosage , Imidazoles/*pharmacokinetics , Microtubule-Associated Proteins/*antagonists & inhibitors , Naphthoquinones/*administration & dosage , Naphthoquinones/*pharmacokinetics , Neoplasm Proteins/*antagonists & inhibitors , Neoplasms/*drug therapy, Adult ; Aged ; Antineoplastic Agents/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Imidazoles/adverse effects ; Infusions, Intravenous ; Inhibitor of Apoptosis Proteins ; Male ; Maximum Tolerated Dose ; Microtubule-Associated Proteins/metabolism ; Middle Aged ; Naphthoquinones/adverse effects ; Neoplasm Proteins/metabolism ; Neoplasms/metabolism ; Neoplasms/pathology ; Pilot Projects ; Survivin ; Treatment Outcome

المؤلفون: Gibbons J; Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA., Egorin MJ, Ramanathan RK, Fu P, Mulkerin DL, Shibata S, Takimoto CH, Mani S, LoRusso PA, Grem JL, Pavlick A, Lenz HJ, Flick SM, Reynolds S, Lagattuta TF, Parise RA, Wang Y, Murgo AJ, Ivy SP, Remick SC

مؤلفون مشاركون: National Cancer Institute Organ Dysfunction Working Group

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2008 Feb 01; Vol. 26 (4), pp. 570-6.

نوع المنشور: Clinical Trial, Phase I; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Kidney Diseases/*etiology , Neoplasms/*complications , Neoplasms/*drug therapy , Piperazines/*administration & dosage , Piperazines/*pharmacokinetics , Pyrimidines/*administration & dosage , Pyrimidines/*pharmacokinetics, Administration, Oral ; Adolescent ; Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/pharmacokinetics ; Area Under Curve ; Benzamides ; Biological Availability ; Creatinine/blood ; Creatinine/urine ; Female ; Half-Life ; Humans ; Hypophosphatemia/chemically induced ; Imatinib Mesylate ; Kidney Diseases/metabolism ; Kidney Function Tests ; Male ; Middle Aged ; Piperazines/adverse effects ; Pyrimidines/adverse effects

المؤلفون: Khambata-Ford S; Bristol-Myers Squibb Co, Princeton, NJ 08543, USA. shirin.ford@bms.com, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2007 Aug 01; Vol. 25 (22), pp. 3230-7.

نوع المنشور: Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Genes, ras* , Mutation*, Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Colorectal Neoplasms/*drug therapy , Colorectal Neoplasms/*genetics , Epidermal Growth Factor/*genetics , Glycoproteins/*genetics , Intercellular Signaling Peptides and Proteins/*genetics, Adult ; Aged ; Aged, 80 and over ; Amphiregulin ; Antibodies, Monoclonal, Humanized ; Biomarkers, Tumor/analysis ; Cetuximab ; EGF Family of Proteins ; Enzyme-Linked Immunosorbent Assay ; Epidermal Growth Factor/metabolism ; Epiregulin ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Female ; Gene Expression Profiling ; Glycoproteins/metabolism ; Humans ; Intercellular Signaling Peptides and Proteins/metabolism ; Male ; Middle Aged ; Neoplasm Metastasis ; Predictive Value of Tests ; Proportional Hazards Models ; Survival Rate ; Treatment Outcome

المؤلفون: Takimoto CH, Mita AC

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2006 Jul 20; Vol. 24 (21), pp. 3509-10; author reply 3510-1.

نوع المنشور: Comment; Letter

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Dietary Supplements*, Antimetabolites, Antineoplastic/*adverse effects , Folic Acid/*administration & dosage , Folic Acid Antagonists/*adverse effects , Glomerular Filtration Rate/*drug effects , Glutamates/*adverse effects , Guanine/*analogs & derivatives , Kidney/*drug effects, Antimetabolites, Antineoplastic/administration & dosage ; Clinical Trials as Topic/standards ; Drug Administration Schedule ; Folic Acid Antagonists/administration & dosage ; Glutamates/administration & dosage ; Guanine/administration & dosage ; Guanine/adverse effects ; Humans ; Kidney/physiopathology ; Pemetrexed ; Research Design

المؤلفون: Tolcher AW; Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA. atolcher@idd.org, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA, Smetzer L, Van Wart Hood J, Merritt J, Rowinsky EK, Takimoto C, Von Hoff D, Eckhardt SG

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2006 May 01; Vol. 24 (13), pp. 2052-8.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Genes, p53* , Genetic Therapy*, Adenoviruses, Human/*genetics , Cytomegalovirus/*genetics , Neoplasms/*therapy, Adult ; Aged ; Antibodies, Viral/blood ; Blood Coagulation/drug effects ; DNA/analysis ; DNA/blood ; Female ; Genetic Vectors ; Humans ; Male ; Middle Aged ; Neoplasms/blood ; Partial Thromboplastin Time ; Promoter Regions, Genetic

المؤلفون: Mita AC; Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA., Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, Tolcher AW, Villalona-Calero M, Sandler A, Chaudhuri T, Molpus K, Latz JE, Simms L, Chaudhary AK, Johnson RD, Rowinsky EK, Takimoto CH

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2006 Feb 01; Vol. 24 (4), pp. 552-62. Date of Electronic Publication: 2006 Jan 03.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antimetabolites, Antineoplastic/*administration & dosage , Antimetabolites, Antineoplastic/*pharmacokinetics , Glutamates/*administration & dosage , Glutamates/*pharmacokinetics , Guanine/*analogs & derivatives , Kidney Failure, Chronic/*complications , Kidney Failure, Chronic/*metabolism , Neoplasms/*complications , Neoplasms/*drug therapy, Adult ; Aged ; Antimetabolites, Antineoplastic/adverse effects ; Antimetabolites, Antineoplastic/blood ; Antimetabolites, Antineoplastic/urine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Diarrhea/chemically induced ; Drug Administration Schedule ; Fatigue/chemically induced ; Female ; Folic Acid/administration & dosage ; Glutamates/adverse effects ; Glutamates/blood ; Glutamates/urine ; Guanine/administration & dosage ; Guanine/adverse effects ; Guanine/blood ; Guanine/pharmacokinetics ; Guanine/urine ; Humans ; Kidney Failure, Chronic/blood ; Kidney Failure, Chronic/urine ; Male ; Middle Aged ; Nausea/chemically induced ; Neutropenia/chemically induced ; Pemetrexed ; Thrombocytopenia/chemically induced ; Vitamin B 12/administration & dosage

المؤلفون: Grem JL; Nebraska Medical Center, Omaha, NE 68198-7680, USA. jgrem@unmc.edu, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2005 Mar 20; Vol. 23 (9), pp. 1885-93.

نوع المنشور: Clinical Trial; Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print Cited Medium: Print ISSN: 0732-183X (Print) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Neoplasms/*drug therapy , Rifabutin/*analogs & derivatives , Rifabutin/*therapeutic use, Adult ; Aged ; Area Under Curve ; Benzoquinones ; Dose-Response Relationship, Drug ; Female ; Half-Life ; Humans ; Infusions, Intravenous ; Lactams, Macrocyclic ; Liver Function Tests ; Male ; Middle Aged ; Rifabutin/adverse effects ; Rifabutin/pharmacokinetics